Search

Displaying results 321 - 330 of 10000 in total
  1. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    [L47026] DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading to a deficiency in functional dystrophin protein. … Delandistrogene moxeparvovec is an adeno-associated virus vector-based gene therapy developed by Sarepta Therapeutics.

  2. Drug

    Bumetanide

    go.drugbank.com/drugs/DB00887
    ApprovedInvestigational

    Bumetanide is a sulfamyl diuretic.

    Mixtures: BURINEX TABLET 1 mg, BURINEX TABLET 1 mgCategories: Increased Diuresis at Loop of Henle
  3. Drug

    Memantine

    go.drugbank.com/drugs/DB01043
    ApprovedInvestigational

    Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). … In December 2013, the G8 dementia summit concluded that dementia should be considered a global priority with the objective of developing a cure or a disease-modifying therapy by the year 2025 [L5953, F4366

    Mixtures: EMAXIN BASLANGIC SETI, 7+7+7+7 ADET, EMAXIN BASLANGIC SETI, 7+7+7+7 ADETCategories: N-methyl-D-aspartate Receptor Antagonist, NMDA Receptor Antagonists
  4. Drug

    Azosemide

    go.drugbank.com/drugs/DB08961
    Investigational

    Azosemide is a loop diuretic used to treat hypertension, edema, and ascites.

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: 2-chloro-5-(1H-tetrazol-5-yl)-N4-2-thenylsulfanilamide, 5-(4'-chloro-5'-sulfamoyl-2'-thenylaminophenyl)tetrazole
  5. Drug

    Dabigatran etexilate

    go.drugbank.com/drugs/DB06695
    ApprovedInvestigational

    Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor dabigatran. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom ...

    Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingProducts: PRADAXA® 150 MG, DABITROM® 150
  6. Drug

    Eptinezumab

    go.drugbank.com/drugs/DB14040
    ApprovedInvestigational

    [L12318] Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human calcitonin gene-related peptide (CGRP). … Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (_Pichia pastoris_) and developed by Lundbeck Seattle Biopharmaceuticals.

    Categories: Calcitonin Gene-related Peptide Antagonist, Calcitonin Gene-Related Peptide (CGRP) AntagonistsProducts: Vyepti® 100 mg/mL concentrate for solution for infusion
  7. Drug

    Sacituzumab govitecan

    go.drugbank.com/drugs/DB12893
    ApprovedInvestigational

    [A193653] Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. … [A193671] One such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2 (TROP-2) antibody with the topoisomerase I inhibitor SN-38.

    Categories: Trop-2-Directed Monoclonal AntibodiesProducts: TRODELVY®, TRODELVY 200 MG İNFÜZYONLUK ÇÖZELTİ KONSANTRESİ İÇİN TOZ, 1 ADET
  8. Drug

    Lovotibeglogene autotemcel

    go.drugbank.com/drugs/DB18680
    ApprovedInvestigational

    Specifically, lovotibeglogene autotemcel provides a functional copy of a modified beta-globin gene (β<sup>A-T87Q</sup>-globin) that when combined with α-globin, produces hemoglobins with similar oxygen-binding … Lovotibeglogene autotemcel consists of autologous hematopoietic stem and progenitor cells transduced with the BB305 lentiviral vector encoding a modified β-globin gene.

    Categories: Autologous Hematopoietic Stem Cell-Based Gene Therapy
  9. Drug

    Seladelpar

    go.drugbank.com/drugs/DB12390
    ApprovedInvestigational

    Seladelpar is a peroxisome proliferator-activated receptor (PPAR)-delta (δ) agonist. Seladelpar is a single enantiomer of the R-configuration. … [L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism

    Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSynonyms: (4-(((2R)-2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)SULFANYL)-2-METHYLPHENOXY)ACETIC ACID PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR (PPAR) AGONIST,ANTIHYPERLIPIDAEMIC, (R)-2-(4-((2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)-THIO)-2-METHYLPHENOXY)ACETIC ACID
  10. Drug

    Black cohosh

    go.drugbank.com/drugs/DB13975
    ApprovedInvestigational

    For these reasons, there has been a trend toward using alternative therapies to relieve menopausal symptoms.[L2301] Black cohosh has been associated with serious safety concerns. … [A32542] Results from studies suggest that C. racemosa possesses a central activity instead of a hormonal effect.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors